Accès ouvert
2024
article
OpenAlex
Eugenio De Corso, Dario Antonio Mele, Angela Rizzi, Camilla Spanu et autres
BACKGROUND/OBJECTIVES: Benralizumab is a monoclonal antibody that targets the interleukin-5 receptor (IL-5Rα), leading to the rapid depletion of blood eosinophils. RCTs have demonstrated efficacy in patients with severe eosinophilic asthma (SEA). The aim of this study was to assess the efficacy of …
it
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Eugenio De Corso, Davide Paolo Porru, Marco Corbò, Claudio Montuori et autres
INTRODUCTION: Management of severe chronic rhinosinusitis with nasal polyps (CRSwNP) has changed significantly in recent years, with different treatments now available including biologics and endoscopic sinus surgery (ESS), although there are still few comparative studies. We aimed to compare 1-year outcomes of …
it
(code pays fourni par la source)
2023
article
OpenAlex
Eugenio De Corso, Claudio Montuori, Silvia Baroni, Rodolfo Francesco Mastrapasqua et autres
it, jp
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Sara Torretta, Eugenio De Corso, Nicolò Nava, Francesca Fraccaroli et autres
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a common disease of the nose and paranasal sinuses with important economic and sanitary burdens, as well as having a great impact on patients' quality of life. In this field, a new therapeutic approach for …
it, ca
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Eugenio De Corso, Silvia Baroni, Stefano Settimi, Maria Elisabetta Onori et autres
The complex pathophysiology of chronic rhinosinusitis with nasal polyps (CRSwNP) generates a spectrum of phenotypes with a wide variety of inflammatory states. We enrolled 44 very-likely-to-be type 2 CRSwNP patients in order to evaluate the load of inflammation and to analyze human …
it
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Eugenio De Corso, Stefano Settimi, Claudio Montuori, Marco Corbò et autres
The aim of this study was to evaluate the efficacy of dupilumab in the treatment of severe uncontrolled Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), with or without asthma as add-on therapy with intra-nasal corticosteroids in a real-life setting over the first year …
it
(code pays fourni par la source)